Categories Uncategorized

Massachusetts Legislators Introduce Bills to Study Psychedelics, Remove Criminal Penalties

Last week, legislators in Massachusetts introduced initiatives that may help end the war on drugs in the state. One measure would establish a task force whose focus will be to study fungi and plant-based psychedelics, its objective being to regulate and legalize these substances. The  second other proposal would do away with criminal penalties for drug possession.

This isn’t the only call to end criminal prohibition in the state. Recently, the city councils of Cambridge and Somerville adopted initiatives that made possession of psychedelics among the lowest law enforcement priorities for their municipalities.

HD 3439, which was introduced to the House by Reps. Mike Connolly and Liz Miranda, would establish a civil fine of $50 for possession of controlled substances. SD 2248, a senate version of the bill that is almost identical to the House legislation, was introduced by Senator Julian Andre Cyr. A separate House legislation that would take the state past decriminalization and permit regulated sales of some drugs was also introduced by Connolly.

To begin with, HD 3829 would set up an interorganizational task force whose purpose would be to study the social justice and public health consequences of legalizing the distribution, consumption, transportation and possession of naturally grown, entheogenic fungi and plants. The legislation states that the task force, which will be made up of 21 people, will study the effects of fungi and plant-based psychedelics and provide suggestions regarding how to legalize these psychedelic substances in a way that would maximize both the sustainable manufacture of these entheogens as well as equitable access.

The initiative also demands that the task force provide counsel around “equity and expungement measures, diversion, parole and pardons” for individuals who have criminal records because of the distribution or possession of controlled substances.

Massachusetts is not the only state considering measures that do away with drug penalties. In California, Sen. Scott Wiener introduced a bill that would legalize the social sharing and possession of some drugs including MDMA, psilocybin mushrooms, DMT, LSD, ibogaine, mescaline and ketamine. The legislation would also offer expungement of past criminal records for the use or possession of psychedelic substances.

Additionally, the state of California would set up a task force under the initiative to study the possible future systems of regulation around psychedelics. The task force will be required to present a report on its findings by 2024.

Lawmakers in the states of Virginia, Connecticut, Washington State, Florida, Kansas and Hawaii are also considering drug policy and psychedelics reform legislations for the 2021 session.

The momentum in favor of psychedelics is also manifesting on the business front. For instance, XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) has set its sights on producing active pharmaceutical ingredients (“API”) from psychedelic compounds on an industrial scale.

NOTE TO INVESTORS: The latest news and updates relating to XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) are available in the company’s newsroom at https://ibn.fm/XPHYF

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)

For more information please visit https://www.psychedelicnewswire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.

Chris@PNW

Share
Published by
Chris@PNW

Recent Posts

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Subsidiary to Acquire 49% Stake in Prominent Florida Neuropsychiatry Clinic

The acquisition of Cohen and Associates, a respected interventional psychiatry practice, by NRx subsidiary HOPE…

2 weeks ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Applies for FDA Commissioner’s National Priority Voucher for IV Ketamine NRX-100

The new FDA voucher program aims to speed approval of drugs aligned with national health…

3 weeks ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Files Abbreviated New Drug Application for Preservative-Free IV Ketamine NRX-100 Amid Ongoing Shortage

The company targets all current ketamine indications, including anesthesia and pain management. The U.S. is…

1 month ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Signs Agreement to Acquire Kadima to Launch $100M Psychiatry Clinic Network

The Kadima Neuropsychiatry Institute acquisition is part of NRx subsidiary HOPE Therapeutics’ model for a…

2 months ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Announces $10.3 Million Financing to Expand HOPE Clinic Network, Advances FDA Drug Approval

Subsidiary HOPE Therapeutics signed a $7.8 million debt financing term sheet with Universal Capital. Combined…

2 months ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Subsidiary, HOPE Therapeutics, to Expand Interventional Psychiatry Treatment with Kadima Institute Acquisition

Kadima Neuropsychiatry Institute is expected to become the clinical model for HOPE Therapeutics’ nationwide network…

2 months ago